Bristol Myers Rolls Out Long-Term Data For Mavacamten In Heart Disease

Comments
Loading...
  • Bristol Myers Squibb & Co BMY has announced long-term data from a mavacamten study acquired via a $13 billion MyoKardia buyout. 
  • Heart patients who received mavacamten in a cohort of the long-term MAVA-LTE study saw significant reductions in median levels of a hormone called NT-proBNP (58% at week 24 and 67% at week 48).
  • Bristol Myers called this a “sustained reduction,” adding that improvements in left ventricular relaxation and diastolic function were also seen. However, no significant changes were observed in left-ventricular stroke volume.
  • Mavacamten was “well-tolerated” in the long-term study, Bristol Myers said. However, nine patients paused their treatment because left ventricular ejection fractions were too low. 
  • Eight of them resumed treatment at a lower dose after recovery, while one discontinued the trial permanently.
  • Price Action: BMY shares closed at $59.43 on Friday.
BMY Logo
BMYBristol-Myers Squibb Co
$53.19-3.62%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
83.74
Growth
35.14
Quality
-
Value
13.97
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In: